Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT05502562
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05498610
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 245
- Registration Number
- NCT05486065
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Velocity Clin Res Gardena, Gardena, California, United States
🇺🇸First Valley Med Grp Lancaster, Lancaster, California, United States
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05479591
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT05478252
- Locations
- 🇿🇦
Precise Clinical Solutions (Pty) Ltd, Durban, KwaZulu-Natal, South Africa
🇿🇦Dr Pillay's Rooms, Durban, KwaZulu-Natal, South Africa
🇵🇱PANSTWOWY INSTYTUT MEDYCZNY MSWiA, Warszawa, Poland
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05473286
A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE)
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 314
- Registration Number
- NCT05468632
- Locations
- 🇲🇰
Novo Nordisk Investigational Site, Veles, North Macedonia
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT05443568
- Locations
- 🇮🇱
Novo Nordisk Investigational Site, Kfar Saba, Israel
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
Phase 3
Withdrawn
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05444153
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 465
- Registration Number
- NCT05443334
- Locations
- 🇪🇸
Master Centre for Spain, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath